# Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

> **NCT04072887** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 974 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** QBW251
- **DRUG:** Placebo
- **DRUG:** COPD maintenance background therapy

## Key facts

- **NCT ID:** NCT04072887
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-12
- **Primary completion:** 2021-10-08
- **Final completion:** 2022-02-01
- **Target enrollment:** 974 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072887, "Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04072887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*